No Data
Thermo Fisher Scientific's (NYSE:TMO) 14% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period
CytoReason Secures $80M From OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts
New funding will expand CytoReason's disease models and proprietary data, enabling R&D leaders at partner companies to make strategic decisions with greater speed and precision.TEL AVIV, Israel--(
NIH Outlays Rise by 5% in June, Says Baird
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
Jefferies Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Maintains Target Price $650
Jefferies analyst Tycho Peterson maintains $Thermo Fisher Scientific(TMO.US)$ with a buy rating, and maintains the target price at $650.According to TipRanks data, the analyst has a success rate of 56
silversurfer222 : ahhhh credit cards... the beast system of church and state ... the fools flock to be saved from the hell they are already in
...
don't ask the Christians to save you they do nothing while waiting for a second coming that isn't coming...
christ consciousness buffoons